Traws Pharma, Inc. Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable
Traws Pharma, Inc. (TRAW) had Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable of 485.17 thousand shares as of 2020-12-31, per its 10-K filed 2021-03-18.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Option, Exercise Price Range, Beginning of Period
us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions · last filed 2021-03-18
- 2020-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable 485.17K shares.
- 2019-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable 245.52K shares.
- 2015-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable 3.23M shares.
- 2014-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable 2.64M shares.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable |
|---|---|
| 2020-12-31 | 485.17K shares 10-K · filed 2021-03-18 |
| 2019-12-31 | 245.52K shares 10-K · filed 2020-03-27 |
| 2015-12-31 | 3.23M shares 10-K · filed 2016-03-28 |
| 2014-12-31 | 2.64M shares 10-K · filed 2015-03-30 |
| 2013-12-31 | 2.35M shares 10-K · filed 2014-03-20 |
| 2013-09-30 | 2.18M shares 10-Q · filed 2013-11-14 |
| 2013-06-30 | 1.79M shares 10-Q · filed 2013-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |